Category Archives: Public Policy

Latest From Public Policy

“II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

N_logo_2clr

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys in the Boston office of Nutter McClennen & Fish LLP. On February 5, 2016, the Patent Trial and Appeal Board (“PTAB”) issued a decision to institute an Inter Partes Review (“IPR”) of Genentech’s “Cabilly II” patent (U.S. Patent No. 6,331,415). This triggered the one-month deadline for third parties to request joinder under 37 CFR § 42.122(b).  Whether you are a licensee, or otherwise Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

#BIOCEO16 Fireside Chat with Senator Chuck Schumer

CEO2013_115x75_Thumbnail copy

New York Senator Chuck Schumer joined attendees at the 2016 BIO CEO & Investor Conference this afternoon for a fireside chat, moderated by BIO Chairman Ron Cohen, to discuss current political and public policy issues facing the country and the biopharmaceutical industry. The Senator expressed optimism that progress can be made on a bipartisan basis in a number of areas that will be conducive to investment in medical innovation and the well-paying jobs that such Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

Tomorrow: From Volume to Value: Designing a Patient-Centered Healthcare System (Webcast)

new-bio-logo

Tomorrow at the Newseum, The Hill will be hosting a live discussion about the transition from volume-based to value-based care. A live webcast will be available for the event, which begins at 8:30 am ET. Last week, Jim Robinson, President of Astellas Pharma US, shared his thoughts in a related op-ed at The Hill. Biopharmaceutical innovation is transforming what it means to be a patient battling some of our most difficult diseases, such as cancer, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Know Your IP Strategy: A Necessity for Technology Start-ups

Annemarie_Meike

The Licensing Executives Society Foundation invites start-up companies, with investments of less than $200,000, and graduate students from around the world to participate in their annual International Business Plan Competition. The Competition requires participants to submit a business plan with an intellectual property component and strategies explaining how intellectual property will be used to achieve business objectives. Before the first round submission deadline, the Competition pairs registered teams with senior leaders in the intellectual property Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post

Patently Biotech’s Top Articles of 2015

Intellectual property and patent reform have dominated headlines in 2015. As we close out the year, let’s take a look at some of this year’s most memorable Patently BIOtech coverage. Here are Patently Biotech’s top blog posts of 2015: This Independence Day, Let’s Thank the Inventors IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma FDA Acts on Biosimilars Seventy Nine House Members Express Concern with H.R. 9 Make sure Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post